Immunotherapy for Lewis lung carcinoma utilizing dendritic cells infected with CK19 gene recombinant adenoviral vectors

Sun,Q. F.; Zhao,X. N.; Peng,C.  L.; Hao,Y. T.; Zhao,Y. P.; Jiang,N.; Xue,H.; Guo,J. Z.; Yun,C. H.; Cong,B.; Zhao,X. G.

doi:10.3892/or.2015.4231

Immunotherapy for Lewis lung carcinoma utilizing dendritic cells infected with CK19 gene recombinant adenoviral vectors

Authors:
- Q. F. Sun
- X. N. Zhao
- C. L. Peng
- Y. T. Hao
- Y. P. Zhao
- N. Jiang
- H. Xue
- J. Z. Guo
- C. H. Yun
- B. Cong
- X. G. Zhao
View Affiliations

Affiliations: Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, Shandong, P.R. China, Department of Comprehensive Health Ⅱ, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China
Published online on: August 27, 2015 https://doi.org/10.3892/or.2015.4231
Pages: 2289-2295
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dendritic cells (DCs) as ʻprofessionalʼ antigen-presenting cells (APCs) initiate and regulate immune responses to various antigens. DC-based vaccines have become a promising modality in cancer immunotherapy. Cytokeratin 19 (CK19) protein is expressed at high levels in lung cancer and many other tumor cells, suggesting CK19 as a potential tumor‑specific target for cancer immune therapy. We constructed a recombinant adenoviral vector containing the CK19 gene (rAd-CK19). DCs transfected with rAd-CK19 were used to vaccinate C57BL/6 mice bearing xenografts derived from Lewis lung carcinoma (LLC) cells. The transfected DCs gave rise to potent CK19-specific cytotoxic T lymphocytes (CTLs) capable of lysing LLC cells. Mice immunized with the rAd‑CK19-DCs exhibited significantly attenuated tumor growth (including tumor volume and weight) when compared to the tumor growth of mice immunized with rAd-c DCs or DCs during the 24-day observation period (P<0.05). The results revealed that the mice vaccinated with the rAd-CK19-DCs exhibited a potent protective and therapeutic antitumor immunity to LLC cells in the subcutaneous model along with an inhibitive effect on tumor growth compared to the mice vaccinated with the rAd-c DCs or DCs alone. The present study proposes a meaningful mode of action utilizing rAd-CK19 DCs in lung cancer immunotherapy.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLoBoCAn 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
2	Collins LG, Haines C, Perkel R and Enck RE: Lung cancer: Diagnosis and management. Am Fam Physician. 75:56–63. 2007.PubMed/NCBI
3	Moscatello DK, Ramirez G and Wong AJ: A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res. 57:1419–1424. 1997.PubMed/NCBI
4	Heimberger AB, Crotty LE, Archer GE, et al: Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 9:4247–4254. 2003.PubMed/NCBI
5	Ciesielski MJ, Kazim AL, Barth RF and Fenstermaker RA: Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother. 54:107–119. 2005. View Article : Google Scholar
6	Paine R, Gaposchkin D, Kelly C and Wilcoxen SE: Regulation of cytokeratin expression in rat lung alveolar epithelial cells in vitro. Am J Physiol. 269:L536–L544. 1995.PubMed/NCBI
7	Kosacka M and Jankowska R: The prognostic value of cytokeratin 19 expression in non-small cell lung cancer. Pneumonol Alergol Pol. 75:317–323. 2007.In Polish.
8	Overwijk WW, Tsung A, Irvine KR, et al: gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 188:277–286. 1998. View Article : Google Scholar : PubMed/NCBI
9	Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature. 392:245–252. 1998. View Article : Google Scholar : PubMed/NCBI
10	Steinman RM and Dhodapkar M: Active immunization against cancer with dendritic cells: The near future. Int J Cancer. 94:459–473. 2001. View Article : Google Scholar : PubMed/NCBI
11	Nyberg-Hoffman C, Shabram P, Li W, Giroux D and Aguilar-Cordova E: Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med. 3:808–811. 1997. View Article : Google Scholar : PubMed/NCBI
12	Morelli AE, Larregina AT, Ganster RW, et al: Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol. 74:9617–9628. 2000. View Article : Google Scholar : PubMed/NCBI
13	Huang AY, Golumbek P, Ahmadzadeh M, et al: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:961–965. 1994. View Article : Google Scholar : PubMed/NCBI
14	Sharma S, Stolina M, Luo J, et al: Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol. 164:4558–4563. 2000. View Article : Google Scholar : PubMed/NCBI
15	Fields RC, Shimizu K and Mulé JJ: Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA. 95:9482–9487. 1998. View Article : Google Scholar : PubMed/NCBI
16	Schnurr M, Galambos P, Scholz C, et al: Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: An in vitro model for the assessment of tumor vaccines. Cancer Res. 61:6445–6450. 2001.PubMed/NCBI
17	Mitchell MS, Harel W, Kan-Mitchell J, et al: Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann NY Acad Sci. 690:153–166. 1993. View Article : Google Scholar : PubMed/NCBI
18	Kirk CJ and Mulé JJ: Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther. 11:797–806. 2000. View Article : Google Scholar : PubMed/NCBI
19	Klein C, Bueler H and Mulligan RC: Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med. 191:1699–1708. 2000. View Article : Google Scholar : PubMed/NCBI
20	Kim S, Lee JB, Lee GK and Chang J: Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Prostate. 69:938–948. 2009. View Article : Google Scholar : PubMed/NCBI
21	Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA and Crystal RG: Dendritic cells genetically modified with an adenovirus vector encoding the cDnA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med. 186:1247–1256. 1997. View Article : Google Scholar : PubMed/NCBI
22	Ribas A, Butterfield LH, Hu B, et al: Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother. 23:59–66. 2000. View Article : Google Scholar : PubMed/NCBI
23	Kaplan JM, Yu Q, Piraino ST, et al: Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol. 163:699–707. 1999.PubMed/NCBI
24	Cho HI, Kim HJ, Oh ST and Kim TG: In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine. 22:224–236. 2003. View Article : Google Scholar : PubMed/NCBI
25	Zhou Q, Guo AL, Xu CR, An SJ, Wang Z, Yang SQ and Wu YL: A dendritic cell-based tumour vaccine for lung cancer: Full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro. Clin Exp Immunol. 153:392–400. 2008. View Article : Google Scholar : PubMed/NCBI
26	Xie J, Xiong L, Tao X, Li X, Su Y, Hou X and Shi H: Antitumor effects of murine bone marrow-derived dendritic cells infected with xenogeneic livin alpha recombinant adenoviral vectors against Lewis lung carcinoma. Lung Cancer. 68:338–345. 2010. View Article : Google Scholar
27	Rea D, Schagen FH, Hoeben RC, et al: Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol. 73:10245–10253. 1999.PubMed/NCBI
28	Jonuleit H, Tüting T, Steitz J, et al: Efficient transduction of mature CD83⁺ dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Ther. 7:249–254. 2000. View Article : Google Scholar : PubMed/NCBI
29	Miller G, Lahrs S, Shah AB and DeMatteo RP: Optimization of dendritic cell maturation and gene transfer by recombinant adenovirus. Cancer Immunol Immunother. 52:347–358. 2003.PubMed/NCBI
30	Yang Y, Li Q, Ertl HC and Wilson JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 69:2004–2015. 1995.PubMed/NCBI
31	Zhong LP, Zhao SF, Chen GF, Ping FY, Xu ZF and Hu JA: Increased levels of CK19 mRnA in oral squamous cell carcinoma tissue detected by relative quantification with real-time polymerase chain reaction. Arch Oral Biol. 51:1112–1119. 2006. View Article : Google Scholar : PubMed/NCBI
32	Galus R and Wodarski K: Importance of the cytokeratins in cancer diagnosis. Pol Merk Lek. 135:209–211. 2007.
33	Xenidis N, Ignatiadis M, Apostolaki S, et al: Cytokeratin-19 mRnA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 27:2177–2184. 2009. View Article : Google Scholar : PubMed/NCBI
34	Van Trappen Po, Gyselman VG, Lowe DG, et al: Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet. 357:15–20. 2001. View Article : Google Scholar : PubMed/NCBI
35	Visser M, Jiwa M, Horstman A, et al: Intra-operative rapid diagnostic method based on CK19 mRnA expression for the detection of lymph node metastases in breast cancer. Int J Cancer. 122:2562–2567. 2008. View Article : Google Scholar : PubMed/NCBI
36	Chen TF, Jiang GL, Fu XL, Wang LJ, Qian H, Wu KL and Zhao S: CK19 mRnA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemoradiation: An independent prognostic factor. Lung Cancer. 56:105–114. 2007. View Article : Google Scholar
37	van Sprundel RG, van den Ingh TS, Desmet VJ, et al: Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours. Comp Hepatol. 9:42010. View Article : Google Scholar : PubMed/NCBI
38	Ohshio G, Imamura T, Okada N, Yamaki K, Suwa H, Imamura M and Sakahara H: Cytokeratin 19 fragment in serum and tissues of patients with pancreatic diseases. Int J Pancreatol. 21:235–241. 1997. View Article : Google Scholar : PubMed/NCBI
39	Steitz J, Brück J, Steinbrink K, Enk A, Knop J and Tüting T: Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma. Int J Cancer. 86:89–94. 2000. View Article : Google Scholar : PubMed/NCBI
40	Fenstermaker RA and Ciesielski MJ: Immunotherapeutic strategies for malignant glioma. Cancer Control. 11:181–191. 2004.PubMed/NCBI